QUANTRO Therapeutics and IMP Form Research Alliance for Drug Discovery

QUANTRO Therapeutics and the Research Institute of Molecular Pathology (IMP) have entered into a strategic partnership to fast-track transcriptomic drug discovery. This collaboration focuses on decoding transcription factor complexes, which play a crucial role in cancer treatment development. Dr. Johannes Zuber, a leader in functional genetics, will lead the research at the IMP located in Vienna.

The alliance aims to enhance QUANTRO's approach by merging genetic screening technologies to understand transcription factors. These factors, once considered difficult to target, are pivotal in cancer cell behavior. Advances in small molecules that affect these proteins' functions mark significant progress in cancer therapies.

Dr. Michael Bauer, CEO of QUANTRO, highlighted the collaboration's potential to transform undruggable targets into accessible ones, thus accelerating the drug discovery process for diseases currently without treatment options. Dr. Bauer will also attend BIO-Europe in Stockholm, an event for exploring innovative drug discovery approaches.